The company intends to conduct the research work in cooperation with the University of British Columbia and the BC Cancer Agency.
The data from preclinical trials showed anti-cancer activity with VAL-083, a small molecule chemotherapeutic.
DelMar Pharma has submitted an investigational new drug (IND) application with the US Food & Drug Administration (FDA) to conduct clinical trials for VAL-083 in patients with glioblastoma multiforme (GBM).
DelMar Pharma president and CEO Jeffrey Bacha said to develop and commercialize VAL-083 they are leveraging previous human clinical trial data demonstrating activity in GBM, including in patients having failed prior therapies.
"Based on these data, we believe that VAL-083 has potential to offer a new treatment option to physicians and patients," Bacha said.